The Top 50 Generic Drug Producers Had Combined Revenues Of $92bn In 2016

14 August 2016
Pharma

Visiongain’ has launched a new pharma report Pharma Leader Series: Top Generic Drug Producers Market Forecast 2017-2027: North America, Europe, India, Japan, South Africa, MENA.

With patent expiries of blockbuster drugs, the generic drugs industry grows more important to the overall pharmaceutical market. Big Pharma are now realising the potential of generics to become a leading source of revenue over the next 10 years. The increasing penetration of generics in both developed and emerging markets has lead industry giants such as Novartis, Sanofi, Abbott and Pfizer to capitalise on this market. Visiongain’s study provides an assessment of the leading generic drug developers, producers and sellers, assessing their strategies and prospects from 2017.

The visiongain report analyst commented “Visiongain believes the forecast period will see more traditional pharma companies embrace generic business units in order to take advantage of higher growth rates in generics. At the same time, successful generic companies will try to innovate, pursuing more research-based pipeline candidates as well as high-value generics and biosimilars. However, generic drug manufacturers must continuously revise their business models in an attempt to outsmart market challenges. New strategic decisions will have to be made to define their future path. This may include steps such as merging for scale, complementing the generic portfolio with a branded portfolio, or adding new offerings and services in order to provide new revenue streams.

Taking advantage of the opportunities in this fast-growing, extremely competitive market will require generics manufacturers to sustain highly efficient production and distribution capacity and to expand their global presence through targeted acquisitions. Companies will need to be vigilant in taking advantage of growth sectors within the market, and aggressive in their pursuit of first-to-file applications”

Leading companies featured in the report who manufacture generic drugs include Teva, Mylan, Pfizer, Abbott, Novartis, Sanofi, Fresenius Kabi, Sun Pharmaceutical Industries, Dr. Reddy’s, Lupin, EMS, Cipla, Perrigo, Abdi Ibrahim and other leading companies.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Global Vaccines Sales market set to grow to $75bn by 2024” says new Visiongain report

Progress in R&D in the therapeutic vaccine field will yield revolutionary results and answer unmet medical needs. This will also lead to more innovative approaches to vaccine development.

25 June 2019

Read

“Global Inflammatory Bowel Diseases (IBD) Drug Market is estimated to reach $8.6bn by 2024” says new Visiongain report

Revenue growth will be driven by rising incidence and prevalence owing to modern lifestyles and improved awareness and diagnosis.

21 June 2019

Read

“Top 25 Vaccines market set to grow to $41bn by 2024” says new Visiongain report

There is an increasing focus to identify diseases that currently do not have a vaccine.

20 June 2019

Read

“Global Ophthalmic Drugs market set to grow to $33bn by 2024” says new Visiongain report

The market for ophthalmic drugs is a growing one.

17 June 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever